UK researchers have grown ‘mini-placentas’ in the lab and used them to shed light on how the placenta develops and interacts with the inner lining of the womb – findings that could help scientists better understand and, in future, potentially treat pre-eclampsia.
The condition affects some pregnant women, usually during the second half of pregnancy or soon after their baby is delivered.
The new study, published today in Cell Stem Cell, shows that it is possible to experiment on a developing human placenta, rather than merely observe specimens, in order to study major disorders of pregnancy.
Professor Ashley Moffett is a researchers from the Department of Pathology at the University of Cambridge.
He said: “Most of the major disorders of pregnancy – pre-eclampsia, still birth, growth restriction, for example – depend on failings in the way the placenta develops in the first few weeks.
This is a process that is incredibly difficult to study – the period after implantation, when the placenta embeds itself into the endometrium, is often described as a ‘black box of human development’
“Over the past few years, many scientists – including several at Cambridge – have developed embryo-like models to help us understand early pre-implantation development.
“But further development is impeded because we understand so little about the interactions between the placenta and the uterus.”
When interactions between the cells of the endometrium and the cells of the placenta do not work properly, they can lead to complications, such as pre-eclampsia.
The condition occcurs in around six in 100 first pregnancies and can put at risk the health of both the mother and the baby.
Professor Moffett and colleagues at the Friedrich Miescher Institute, Switzerland, and the Wellcome Sanger Institute, Cambridge, have used ‘mini-placentas’ – a cellular model of the early stages of the placenta – to provide a window into early pregnancy and help improve our understanding of reproductive disorders.
Known as ‘trophoblast organoids’, these are grown from placenta cells and model the early placenta so well that they have previously been shown to record a positive response on an over-the-counter pregnancy test.
In the new study, Prof. Moffett’s team applied proteins secreted by the uterine natural killer cells to the trophoblast organoids so that they could mimic the conditions where the placenta implants itself.
The researchers identified particular proteins that were crucial to helping the organoids develop. These proteins will contribute to successful implantation, allowing the placenta to invade the uterus and transform the mother’s arteries.
Prof Moffett said: “This is the only time that we know of where a normal cell invades and transforms an artery, and these cells are coming from another individual, the baby.
“If the cells aren’t able to invade properly, the arteries in the womb don’t open up and so the placenta – and therefore the baby – are starved of nutrients and oxygen.
“That’s why you get problems later on in pregnancy, when there just isn’t enough blood to feed the baby and it either dies or is very tiny.”
The research team also found several genes that regulate blood flow and help with this implantation, which Professor Moffett says provide pointers for future research to better understand pre-eclampsia and similar disorders.
Dr Margherita Turco, from the Friedrich Miescher Institute in Switzerland co-led the work.
The researcher said: “Despite affecting millions of women a year worldwide, we still understand very little about pre-eclampsia.
“Women usually present with pre-eclampsia at the end of pregnancy, but really to understand it – to predict it and prevent it – we have to look at what’s happening in the first few weeks.
“Using ‘mini-placentas’, we can do just that, providing clues as to how and why pre-eclampsia occurs.
“This has helped us unpick some of the key processes that we should now focus on far more.
“It shows the power of basic science in helping us understand our fundamental biology, something that we hope will one day make a major difference to the health of mothers and their babies.”
Image: Friedrich Miescher Institute/University of Cambridge
NHS Forth Valley goes live with RCPCH GrowthAPI integrated with Morse Mobile EPR
Mid and South Essex ICS building new shared care record with Orion Health
Red light can reduce blood glucose levels, study finds
Medical device design standards
Why rethinking funding priorities is key to virtual ward success
Thousands with cancer-causing condition offered life-saving NHS bowel cancer test
Neuromelanin imaging: A new path to brain health insights
Lenus puts automation at heart of diagnostic pathways with CDC Heart Failure roll-out
Gallery will highlight therapeutic power of art
Delays in lockdown skin cancer diagnosis linked to deaths and £6bn costs in Europe
- AI3 weeks ago
ICO seeks permission to appeal Clearview AI Inc’s successful challenge
- Business1 week ago
Meet the CEO at the helm of Iceland’s most exciting business accelerator
- Mental health4 weeks ago
Four out of five support psilocybin for end of life care
- Mental health3 weeks ago
Phone-based therapy ‘better than antidepressants’